Susan Levinson

Patent Covers Use of Plasma Gelsolin to Treat Multiple Sclerosis and to Diagnose Neurologic Diseases BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – March 4, 2013) BioAegis Therapeutics announced today that broad US patent protection for plasma gelsolin to treat Multiple Sclerosis (MS) and to diagnosis neurological disease. MS affects approximately 400,000 people in the …

March 4, 2013: High-Value US Neurological Patent Issued Read More »

BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – March 1, 2013) BioAegis Therapeutics announced today that it has opened a research laboratory facility at the NJ Commercialization Center of Innovative Technology in North Brunswick, New Jersey.

Plans Phase 2b/3 Trial for Biologic in Prevention of Organ Dysfunction in ICU BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – February 7, 2013) BioAegis Therapeutics announced today that it completed it’s initial $3MM convertible note round to fund the companies operating activites in its effort to commercialize groundbreaking discoveries as to plasma gelsolin’s (pGSN) …

February 7, 2013: BioAegis Therapeutics Completes Initial $3MM Raise Read More »

Advisors Engaged to Advance Biomarker-Driven Clinical Program BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – January 15, 2013) BioAegis Therapeutics announced that it has assembled a Critical Care Clinical Advisory Board comprised of world-recognized, highly experienced key opinion leaders. Initial members are: Derek Angus, M.D., Professor and Chair, Critical Care Medicine and Professor, Medicine and …

January 15, 2013: BioAegis Assembles World-Class Clinical Advisory Board Read More »

BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – November 10, 2012) Pursuant to the terms of the agreement with the Brigham and Women’s Hospital previously announced on May 11, 2011, BioAegis Therapeutics elected to exercise its option into an exclusive license to recombinant human plasma gelsolin technology.

BioAegis’ Patent Coverage Expands to Asia Recombinant human plasma gelsolin has demonstrated efficacy against both gram positive and gram negative bacteria and this broad patent filing was recently granted in China. BioAegis is pursuing worldwide patent filings for infectious disease.

BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – August 30, 2012) Lester Kobzik M.D., BioAegis Scientific Advisor and collaborator from Harvard School of Public Health, has made important medical discoveries about plasma gelsolin’s role in boosting immune function to target a broad range of pathogens. Dr. Kobzik is pursuing work in secondary pneumonia under a …

August 30, 2012: NIAID Awards BioAegis Therapeutics’ Scientific Advisor Lester Kobzik $1MM Grant to Further Plasma Gelsolin Research Read More »

Company Requested to Submit White Papers Following IND BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – July 15, 2012) BioAegis Therapeutics Inc. announced that it has presented its plasma gelsolin technology platform to scientists at the Biological Advanced Research Development Agency (BARDA). Data shared at the meeting demonstrated the ability of plasma to address biological …

July 15, 2012: BioAegis Therapeutics Presents to BARDA Scientists for TechWatch Day Read More »

BioAegis’ Patent Rights Extend to Applications for Inflammation Recombinant plasma gelsolin has been shown to be a biomarker of inflammation in a wide range of diseases and in particular in rheumatoid arthritis (RA). This abundant human plasma protein is expected to have utility in patients with RA, as well as other inflammatory diseases.

Plasma Gelsolin Could Hold the Key to the Body’s Ability to Localize Inflammation BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(May 17, 2011) BioAegis Therapeutics, Inc. announced today that it has entered into an Exclusive Option Agreement with Brigham and Women’s Hospital for technology based on research of Dr. Thomas Stossel, Director, Translational Medicine at Brigham and …

May 17, 2011: BioAegis Therapeutics Signs Exclusive Option for Human Protein in Clinical Development Read More »